CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%
China Resources Pharmaceutical (03320.HK) announced the preliminary performance of its subsidiary China Resources Sanjiu (000999.SZ) for the year 2025, with total operating revenue of 31.629 billion RMB, an increase of 14.5% year-on-year. Net profit attributable to shareholders was 3.422 billion RMB, a growth of 1.6%
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments